# A Study of ABTL0812 in Pancreatic Cancer

> **NCT03417921** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Ability Pharmaceuticals SL** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ABTL0812
- **DRUG:** Gemcitabine and nab-paclitaxel

## Key facts

- **NCT ID:** NCT03417921
- **Lead sponsor:** Ability Pharmaceuticals SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-04-26
- **Primary completion:** 2023-04-26
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** We opened another study.
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417921, "A Study of ABTL0812 in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03417921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*